Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.

NCT05817227 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-12-22

No results posted yet for this study

Summary

This is multicentric, spontaneous, observational, retrospective and prospective study.

Conditions

Sponsors & Collaborators

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Alfredo Budillon, M.D. · IRCCS I.N.T. "G. Pascale"

  • Susan Costantini, PhD · IRCCS I.N.T. "G. Pascale"

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2027-11-19
Completion
2027-11-19

Countries

  • Italy

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05817227 on ClinicalTrials.gov